We are live on ! Find out more
CDAK

Codiak BioSciences, Inc. Common Stock

Delisted

CDAK was delisted on the 4th of April, 2023.

56 hedge funds and large institutions have $224M invested in Codiak BioSciences, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 17 increasing their positions, 13 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

133% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 3

31% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 13

8% more funds holding

Funds holding: 5256 (+4)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

14% less capital invested

Capital invested by funds: $260M → $224M (-$36.1M)

100% less call options, than puts

Call options by funds: $0 | Put options by funds: $296K

Holders
56
Holders Change
+4
Holders Change %
+7.69%
% of All Funds
0.98%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
7
Increased
17
Reduced
13
Closed
3
Calls
Puts
$296K
Net Calls
-$296K
Net Calls Change
-$296K

CDAK Hedge Fund Activity: Q3 2021 in Review

56 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Codiak BioSciences, Inc. Common Stock (CDAK) for Q3 2021, worth a combined $224M — down 14% from $260M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new CDAK positions and 3 closed out — a net gain of 4 holders — while 17 added to existing stakes and 13 trimmed.

The largest buyer was Ikarian Capital, opening a new position worth an estimated $2.14M. The largest seller was Franklin Resources, cutting an estimated $6.15M.

  • 56 institutional investors held Codiak BioSciences, Inc. Common Stock (CDAK) as of Q3 2021, up from 52 in Q2 2021.
  • Funds reported $224M of Codiak BioSciences, Inc. Common Stock stock for Q3 2021, down 14% quarter-over-quarter.
  • 7 funds opened new Codiak BioSciences, Inc. Common Stock positions in Q3 2021 and 3 closed out, a net change of +4 holders.
  • The largest Codiak BioSciences, Inc. Common Stock buyer in Q3 2021 was Ikarian Capital, an estimated $2.14M added.
  • The largest Codiak BioSciences, Inc. Common Stock seller in Q3 2021 was Franklin Resources, an estimated $6.15M sold.

Based on aggregated 13F filings for Q3 2021.